Effects of County Public Hospital Reform on Procurement Costs and Volume of Antibiotics: A Quasi-Natural Experiment in Hubei Province, China
Yuqing Tang,
Chaojie Liu,
Junjie Liu,
Xinping Zhang () and
Keyuan Zuo ()
Additional contact information
Yuqing Tang: Huazhong University of Science and Technology
Chaojie Liu: La Trobe University
Junjie Liu: Huazhong University of Science and Technology
Xinping Zhang: Huazhong University of Science and Technology
Keyuan Zuo: Hubei Public Resource Trading Center
PharmacoEconomics, 2018, vol. 36, issue 8, No 10, 995-1004
Abstract:
Abstract Background The overuse of antibiotics has become a major public health challenge worldwide, especially in low- and middle-income countries, including China. In 2009, the Chinese government launched a series of measures to de-incentivise over-prescription in public health facilities, including decoupling the link between facility income and the sale of medicines. Objectives We evaluated the effects of these measures on procurement costs and the volume of antibiotics in county public hospitals. Methods The study was undertaken in the Hubei province of China, where 64 county public hospitals implemented the reform in sequence at three different stages. A quasi-natural experiment design was employed. We performed generalised linear regressions with a difference-in-differences approach using 22,713 procurement records of antibiotics from November 2014 to December 2016. Results The regression results showed that the reform contributed to a 14.79% increase in total costs for antibiotics (p = 0.013), particularly costs for injectable antibiotics (p = 0.022) and first-line antibiotics (p = 0.030). The procurement prices for antibiotics remained largely comparable to those in the control group, but the reform led to a 17.30% increase in the procurement volume (expressed as defined daily doses) of second-line antibiotics (p = 0.032). Conclusions County public hospitals procured more antibiotics and greater numbers of expensive antibiotics, such as those administered via injection, to compensate for the loss of income from the sale of medicines, leading to an increased total cost of antibiotics.
Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)
Downloads: (external link)
http://link.springer.com/10.1007/s40273-018-0654-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:36:y:2018:i:8:d:10.1007_s40273-018-0654-1
Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273
DOI: 10.1007/s40273-018-0654-1
Access Statistics for this article
PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell
More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().